An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms.
Compounds that inhibit cell production of DNA or RNA.
Toxic antibiotic of the mitomycin group, obtained from MITOMYCIN and also from Streptomyces ardus and other species. It is proposed as an antineoplastic agent, with some antibiotic properties.
An oral anticoagulant that interferes with the metabolism of vitamin K. It is also used in biochemical experiments as an inhibitor of reductases.
Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases.
An abnormal triangular fold of membrane in the interpalpebral fissure, extending from the conjunctiva to the cornea, being immovably united to the cornea at its apex, firmly attached to the sclera throughout its middle portion, and merged with the conjunctiva at its base. (Dorland, 27th ed)
Any surgical procedure for treatment of glaucoma by means of puncture or reshaping of the trabecular meshwork. It includes goniotomy, trabeculectomy, and laser perforation.
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)
A flavoprotein that reversibly catalyzes the oxidation of NADH or NADPH by various quinones and oxidation-reduction dyes. The enzyme is inhibited by dicoumarol, capsaicin, and caffeine.
Saturated azacyclopropane compounds. They include compounds with substitutions on CARBON or NITROGEN atoms.
An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.
The mucous membrane that covers the posterior surface of the eyelids and the anterior pericorneal surface of the eyeball.
Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).
The instillation or other administration of drugs into the bladder, usually to treat local disease, including neoplasms.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
That portion of the electromagnetic spectrum immediately below the visible range and extending into the x-ray frequencies. The longer wavelengths (near-UV or biotic or vital rays) are necessary for the endogenous synthesis of vitamin D and are also called antirachitic rays; the shorter, ionizing wavelengths (far-UV or abiotic or extravital rays) are viricidal, bactericidal, mutagenic, and carcinogenic and are used as disinfectants.
A surgical procedure used in treatment of glaucoma in which an opening is created through which aqueous fluid may pass from the anterior chamber into a sac created beneath the conjunctiva, thus lowering the pressure within the eye. (Hoffman, Pocket Glossary of Ophthalmologic Terminology, 1989)
Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS.
The phenomenon by which a temperate phage incorporates itself into the DNA of a bacterial host, establishing a kind of symbiotic relation between PROPHAGE and bacterium which results in the perpetuation of the prophage in all the descendants of the bacterium. Upon induction (VIRUS ACTIVATION) by various agents, such as ultraviolet radiation, the phage is released, which then becomes virulent and lyses the bacterium.
Viruses whose hosts are bacterial cells.
Chemical agents that increase the rate of genetic mutation by interfering with the function of nucleic acids. A clastogen is a specific mutagen that causes breaks in chromosomes.
Patient care procedures performed during the operation that are ancillary to the actual surgery. It includes monitoring, fluid therapy, medication, transfusion, anesthesia, radiography, and laboratory tests.
A Fanconi anemia complementation group protein that regulates the activities of CYTOCHROME P450 REDUCTASE and GLUTATHIONE S-TRANSFERASE. It is found predominately in the CYTOPLASM, but moves to the CELL NUCLEUS in response to FANCE PROTEIN.
A diverse group of proteins whose genetic MUTATIONS have been associated with the chromosomal instability syndrome FANCONI ANEMIA. Many of these proteins play important roles in protecting CELLS against OXIDATIVE STRESS.
An exchange of segments between the sister chromatids of a chromosome, either between the sister chromatids of a meiotic tetrad or between the sister chromatids of a duplicated somatic chromosome. Its frequency is increased by ultraviolet and ionizing radiation and other mutagenic agents and is particularly high in BLOOM SYNDROME.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
Agents that reduce the frequency or rate of spontaneous or induced mutations independently of the mechanism involved.
An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)
A Fanconi anemia complementation group protein that undergoes PHOSPHORYLATION by CDC2 PROTEIN KINASE during MITOSIS. It forms a complex with other FANCONI ANEMIA PROTEINS and helps protect CELLS from DNA DAMAGE by genotoxic agents.
Sterile solutions that are intended for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS.
An error-prone mechanism or set of functions for repairing damaged microbial DNA. SOS functions (a concept reputedly derived from the SOS of the international distress signal) are involved in DNA repair and mutagenesis, in cell division inhibition, in recovery of normal physiological conditions after DNA repair, and possibly in cell death when DNA damage is extensive.
The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.
An antineoplastic agent derived from BLEOMYCIN.
Chemicals used in agriculture. These include pesticides, fumigants, fertilizers, plant hormones, steroids, antibiotics, mycotoxins, etc.
Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.
The study of the physical and chemical properties of a drug and its dosage form as related to the onset, duration, and intensity of its action.
Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form.
The segment of GASTROINTESTINAL TRACT that includes the ESOPHAGUS; the STOMACH; and the DUODENUM.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
Tumors or cancer of the URINARY BLADDER.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
Instruments used for injecting or withdrawing fluids. (Stedman, 25th ed)
The use of a device composed of thermoluminescent material for measuring exposure to IONIZING RADIATION. The thermoluminescent material emits light when heated. The amount of light emitted is proportional to the amount of ionizing radiation to which the material has been exposed.
Polymerized methyl methacrylate monomers which are used as sheets, moulding, extrusion powders, surface coating resins, emulsion polymers, fibers, inks, and films (From International Labor Organization, 1983). This material is also used in tooth implants, bone cements, and hard corneal contact lenses.
A loose confederation of computer communication networks around the world. The networks that make up the Internet are connected through several backbone networks. The Internet grew out of the US Government ARPAnet project and was designed to facilitate information exchange.
The interactions between physician and patient.
Those individuals engaged in research.
Predetermined sets of questions used to collect data - clinical data, social status, occupational group, etc. The term is often applied to a self-completed survey instrument.

Nuclear foci of mammalian recombination proteins are located at single-stranded DNA regions formed after DNA damage. (1/1595)

A sensitive and rapid in situ method was developed to visualize sites of single-stranded (ss) DNA in cultured cells and in experimental test animals. Anti-bromodeoxyuridine antibody recognizes the halogenated base analog incorporated into chromosomal DNA only when substituted DNA is in the single strand form. After treatment of cells with DNA-damaging agents or gamma irradiation, ssDNA molecules form nuclear foci in a dose-dependent manner within 60 min. The mammalian recombination protein Rad51 and the replication protein A then accumulate at sites of ssDNA and form foci, suggesting that these are sites of recombinational DNA repair.  (+info)

Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG). (2/1595)

Tumour-selective acidification is of potential interest for enhanced therapeutic gain of pH sensitive drugs. In this study, we investigated the feasibility of a tumour-selective reduction of the extracellular and intracellular pH and their effect on the tumour response of selected anti-cancer drugs. In an in vitro L1210 leukaemic cell model, we confirmed enhanced cytotoxicity of chlorambucil at low extracellular pH conditions. In contrast, the alkylating drugs melphalan and cisplatin, and bioreductive agents mitomycin C and its derivative EO9, required low intracellular pH conditions for enhanced activation. Furthermore, a strong and pH-independent synergism was observed between the pH-equilibrating drug nigericin and melphalan, of which the mechanism is unclear. In radiation-induced fibrosarcoma (RIF-1) tumour-bearing mice, the extracellular pH was reduced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) or its analogue benzylguanidine (BG) plus glucose. To simultaneously reduce the intracellular pH, MIBG plus glucose were combined with the ionophore nigericin or the Na+/H+ exchanger inhibitor amiloride and the Na+-dependent HCO3-/Cl- exchanger inhibitor 4,4'-diisothiocyanostilbene-2,2'-disulphonic acid (DIDS). Biochemical studies confirmed an effective reduction of the extracellular pH to approximately 6.2, and anti-tumour responses to the interventions indicated a simultaneous reduction of the intracellular pH below 6.6 for at least 3 h. Combined reduction of extra- and intracellular tumour pH with melphalan increased the tumour regrowth time to 200% of the pretreatment volume from 5.7 +/- 0.6 days for melphalan alone to 8.1 +/- 0.7 days with pH manipulation (P < 0.05). Mitomycin C related tumour growth delay was enhanced by the combined interventions from 3.8 +/- 0.5 to 5.2 +/- 0.5 days (P < 0.05), but only in tumours of relatively large sizes. The interventions were non-toxic alone or in combination with the anti-cancer drugs and did not affect melphalan biodistribution. In conclusion, we have developed non-toxic interventions for sustained and selective reduction of extra- and intracellular tumour pH which potentiated the tumour responses to selected anti-cancer drugs.  (+info)

Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials. (3/1595)

BACKGROUND: Oral 5-fluorouracil and its prodrugs (tegafur, carmofur) is now being studied for adjuvant chemotherapy of curatively resected colorectal cancers. To evaluate the effect of these oral fluoropyrimidines (o-FPs), an individual patient data (IPD) meta-analysis of randomized clinical trials was performed in Japan as an inter-trialist group study. METHODS: Data from the three clinical trials in which postoperative adjuvant therapy with o-FPs was compared with surgery alone in patients with colorectal cancer were sought. IPD from a total of 4960 patients with follow-up periods of at least 5 years were analyzed. RESULTS: The results of the meta-analysis on an 'intention to treat' basis demonstrated a significant benefit of o-FPs in terms of the disease-free survival (DFS) of the total patients [risk ratio (RR) 0.830, 95% confidence interval (CI) 0.742-0.929, P = 0.001]. o-FPs were also demonstrated to be effective for survival in rectal cancer (RR 0.857, 95% CI 0.734-0.999, P = 0.049) and in Dukes'C colorectal cancer (RR 0.828, 95% CI 0.711-0.965, P = 0.016). CONCLUSION: The results suggest the advantage of long term o-FPs, possibly with the injection of mitomycin C, for prognosis for curatively resected colorectal cancer patients.  (+info)

Genetic localization and molecular characterization of two key genes (mitAB) required for biosynthesis of the antitumor antibiotic mitomycin C. (4/1595)

Mitomycin C (MC) is an antitumor antibiotic derived biosynthetically from 3-amino-5-hydroxybenzoic acid (AHBA), D-glucosamine, and carbamoyl phosphate. A gene (mitA) involved in synthesis of AHBA has been identified and found to be linked to the MC resistance locus, mrd, in Streptomyces lavendulae. Nucleotide sequence analysis showed that mitA encodes a 388-amino-acid protein that has 71% identity (80% similarity) with the rifamycin AHBA synthase from Amycolatopsis mediterranei, as well as with two additional AHBA synthases from related ansamycin antibiotic-producing microorganisms. Gene disruption and site-directed mutagenesis of the S. lavendulae chromosomal copy of mitA completely blocked the production of MC. The function of mitA was confirmed by complementation of an S. lavendulae strain containing a K191A mutation in MitA with AHBA. A second gene (mitB) encoding a 272-amino-acid protein (related to a group of glycosyltransferases) was identified immediately downstream of mitA that upon disruption resulted in abrogation of MC synthesis. This work has localized a cluster of key genes that mediate assembly of the unique mitosane class of natural products.  (+info)

Phthalascidin, a synthetic antitumor agent with potency and mode of action comparable to ecteinascidin 743. (5/1595)

A series of totally synthetic molecules that are structurally related to the marine natural product ecteinascidin 743 (Et 743) has been prepared and evaluated as antitumor agents. The most active of these, phthalascidin, is very similar to Et 743 with regard to in vitro potency and mode of action across a variety of cell types. The antiproliferative activity of phthalascidin (IC50 = 0.1-1 nM) is greater than that of the agents Taxol, camptothecin, adriamycin, mitomycin C, cisplatin, bleomycin, and etoposide by 1-3 orders of magnitude, and the mechanism of action is clearly different from these currently used drugs. Phthalascidin and Et 743 induce DNA-protein cross-linking and, although they seem to interact with topoisomerase (topo) I (but not topo II), topo I may not be the primary protein target of these agents. Phthalascidin and Et 743 show undiminished potency in camptothecin- and etoposide-resistant cells. Phthalascidin is more readily synthesized and more stable than Et 743, which is currently undergoing clinical trials. The relationship of chemical structure and antitumor activity for this class of molecules has been clarified by this study.  (+info)

Molecular characterization and analysis of the biosynthetic gene cluster for the antitumor antibiotic mitomycin C from Streptomyces lavendulae NRRL 2564. (6/1595)

BACKGROUND: The mitomycins are natural products that contain a variety of functional groups, including aminobenzoquinone- and aziridine-ring systems. Mitomycin C (MC) was the first recognized bioreductive alkylating agent, and has been widely used clinically for antitumor therapy. Precursor-feeding studies showed that MC is derived from 3-amino-5-hydroxybenzoic acid (AHBA), D-glucosamine, L-methionine and carbamoyl phosphate. A genetically linked AHBA biosynthetic gene and MC resistance genes were identified previously in the MC producer Streptomyces lavendulae NRRL 2564. We set out to identify other genes involved in MC biosynthesis. RESULTS: A cluster of 47 genes spanning 55 kilobases of S. lavendulae DNA governs MC biosynthesis. Fourteen of 22 disruption mutants did not express or overexpressed MC. Seven gene products probably assemble the AHBA intermediate through a variant of the shikimate pathway. The gene encoding the first presumed enzyme in AHBA biosynthesis is not, however, linked within the MC cluster. Candidate genes for mitosane nucleus formation and functionalization were identified. A putative MC translocase was identified that comprises a novel drug-binding and export system, which confers cellular self-protection on S. lavendulae. Two regulatory genes were also identified. CONCLUSIONS: The overall architecture of the MC biosynthetic gene cluster in S. lavendulae has been determined. Targeted manipulation of a putative MC pathway regulator led to a substantial increase in drug production. The cloned genes should help elucidate the molecular basis for creation of the mitosane ring system, as well efforts to engineer the biosynthesis of novel natural products.  (+info)

Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: a randomized feasibility study justifying a multicentre phase III trial. (7/1595)

Surgical resection offers the best chance for cure for early stage non-small-cell lung cancer (NSCLC, stage I, II, IIIA), but the 5-year survival rates are only moderate, with systemic relapse being the major cause of death. Pre-operative (neo-adjuvant) chemotherapy has shown promise in small trials restricted to stage IIIA patients. We believe similar trials are now appropriate in all stages of operable lung cancer. A feasibility study was performed in 22 patients with early stage (IB, II, IIIA) resectable NSCLC; randomized to either three cycles of chemotherapy [mitomycin-C 8 mg m(-2), vinblastine 6 mg m(-2) and cisplatin 50 mg m(-2) (MVP)] followed by surgery (n = 11), or to surgery alone. Of 40 eligible patients, 22 agreed to participate (feasibility 55%) and all complied with the full treatment schedule. All symptomatic patients achieved either complete (50%) or partial (50%) relief of tumour-related symptoms with pre-operative chemotherapy. Fifty-five per cent achieved objective tumour response, and a further 27% minor tumour shrinkage; none had progressive disease. Partial pathological response was seen in 50%. No severe (WHO grade III-IV) toxicities occurred. No significant deterioration in quality of life was detected during chemotherapy. Pre-operative MVP chemotherapy is feasible in early stage NSCLC, and this study has now been initiated as a UK-wide Medical Research Council phase III trial.  (+info)

Stimulation of adult human bone marrow by factors secreted by fetal liver hematopoietic cells: in vitro evaluation using semisolid clonal assay system. (8/1595)

Fetal liver infusion (FLI) therapy has been used in various disorders, such as aplastic anemia, leukemia, metabolic disorders, etc., and has been shown to result in stimulation of autologous hematopoiesis in many cases. The aim of the present study was to elucidate the mechanism of stimulation of adult hematopoiesis by fetal liver hematopoietic cells (FLHC) and to identify the factors involved in the process using a clonal assay system in vitro. The effect of FLHC on the clonal growth of bone marrow cells was studied using a co-culture system consisting of mitomycin C-treated FLHC with 2 x 10(5) bone marrow (BM) mononuclear cells. It was observed that FLHC induced a two- to four-fold increase in the BM colony formation. A further increase in the number of FLHC did not, however, result in an equivalent fold increase in the colony formation, indicating that the number of cells in the BM population responsive to FLHC was perhaps the limiting factor. When the effect of fetal liver cell conditioned medium (FLCM) was examined in a similar fashion, it was observed that the FLCM showed a 1.5- to 4-fold increase in the colony formation when used at 1%-5% along with limiting amounts of growth factors. Higher concentrations of conditioned medium resulted in inhibitory responses. One of the principal factors responsible for the stimulatory activity of FLCM was shown to be transforming growth factor-beta1 (TGF-beta1), by a variety of experiments such as its quantitation in FLCM by enzyme-linked immunosorbent assay, antibody neutralization, and reconstruction experiments using purified TGF-beta1 and normal medium. In these reconstitution experiments, TGF-beta1 stimulated the colony formation when it was applied at 1-50 pg/ml, but at higher concentration it induced an inhibitory effect, mimicking the behavior earlier seen with FLCM. Our data strongly suggest that one of the mechanisms in stimulation of a recipient's hematopoiesis could be mediated by the action of TGF-beta1 secreted by infused FLHC and could provide a rational framework on which FLI therapy can be further evaluated.  (+info)

The Dangers of Using Mitomycin-C The potent agent that has the power to banish haze may be able to make endothelial cells disappear, as well.. Mitomycin is FDA approved for the...Mitomycin C: mechanism of action, usefulness and limitations.. Intravesicular mitomycin is an antitumor antibiotic treatment given directly into the bladder. However, it can occur with any instillation.The purpose of this study is to compare the bladder cancer treatments, Mitomycin C (MMC) and Bacillus Calmette Guerin (BCG), to find out which is better.Mitomycin - Drug Info, Side Effects, Research, Clinical Trials. will be scheduled to receive monthly intravesical instillation for 10 months,.Mitomycin C is given as a chemotherapy,. mitomycin c intravesical Instillation. here in video we have instilled 40 mg of Mitomycin,.Mitomycin C is a mitomycin that is used as a chemotherapeutic agent by virtue of its antitumour. as well as by bladder instillation for superficial bladder tumours.. EAUN15 Guideline Intravesical ...
Mitomycin C is a mitomycin that is used as a chemotherapeutic agent by virtue of its antitumour activity. It is given intravenously to treat upper gastro-intestinal cancers (e.g. esophageal carcinoma), anal cancers, and breast cancers, as well as by bladder instillation for superficial bladder tumours. It causes delayed bone marrow toxicity and therefore it is usually administered at 6-weekly intervals. Prolonged use may result in permanent bone-marrow damage. It may also cause lung fibrosis and renal damage. Mitomycin C has also been used topically rather than intravenously in several areas. The first is cancers, particularly bladder cancers and intraperitoneal tumours. It is now well known that a single instillation of this agent within 6 hours of bladder tumor resection can prevent recurrence. The second is in eye surgery where mitomycin C 0.02% is applied topically to prevent scarring during glaucoma filtering surgery and to prevent haze after PRK or LASIK; mitomycin C has also been shown to ...
Differential Effects of Mitomycin C on Constitutive and Inducible Gene Expression in the Chicken Embryo Liver In Vivo: Correlation with Developmental Age and Chromatin Structure A Thesis Submitted to the Faculty in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Pharmacology and Toxicology by Rosemary M. Caron DARTMOUTH COLLEGE Hanover, New Hampshire October 13, 1995 ...
During my first ten years on the Yale faculty, I participated in clinical trials evaluating the efficacy of bioreductive alkylating agents as an adjunct to radiotherapy in cervix cancer. A Phase III study comparing radiotherapy alone with radiotherapy plus Mitomycin C for cervix cancer has been completed in Venezuela with results showing a significant improvement in disease-free survival with the addition of Mitomycin C, which is a hypoxic cell cytotoxin. For several years, I had been collaborating with Interventional Cardiology and Medical Physics in a clinical program utilizing coronary brachytherapy to manage in-stent restenosis. Some current or upcoming clinical research projects include: 1) modifying radiation dose and volume in advanced stage Hodgkins disease based on response to initial chemotherapy (a cooperative group trial); 2) the effects of prostate edema during brachytherapy on modulating radiation dose delivery; 3) the changes in second malignancies seen after Hodgkins Lymphoma ...
Micronucleus (MN) assay is a well standardized approach for evaluation of clastogenic/aneugenic effects of mutagens. Fluorescence in situ hybridization (FISH) is successfully used to characterize the chromosomal content of MN. However, the relationships between nuclear positioning, length, and gene density of individual chromosomes and their involvement in MN induced by different mutagens have not been clearly defined. Chromosomal content of MN was characterized in human leukocytes treated with mitomycin C (MMC) and bleomycin (BLM) by FISH using centromeric (cep) and whole-chromosome painting (wcp) probes. Involvement of chromosomes 8, 15 and 20 in MMC-induced and chromosomes 1, 9 and 16 in BLM-induced MN was studied, and correlated with chromosome size, gene density and interphase position. The results obtained were analyzed together with previous own data on the frequencies of inclusion of chromosomes 3, 4, 6, 7, 9, 16, 17, 18, and X in MMC-induced MN. It could be shown that MMC- and BLM-induced MN
Object. The authors conducted a study to determine the effectiveness of mitomycin C (MMC) in preventing epidural fibrosis in rats which underwent craniectomy. Methods. Craniectomies were performed in the right frontoparietal region; after the procedure the animals had been divided in 2 groups of 10 each. Cotton pads soaked with 0.1mg/ml MMC or saline (control) were applied to the operative sites. Four weeks after craniectomy the rats were sacrificed, and epidural fibrosis was evaluated histologically. The dura mater thickness, the density of epidural fibrosis, arachnoidal involvement, and bone regeneration were determined. Results. No obvious adhesion formed in the rats in the MMC group, but severe epidural adhesions were found in control group. The duramater thickness, the density of epidural fibrosis, and arachnoidal involved rat number in the MMC group were significantly lower than in control groups. Conclusions. Epidural fibrosis can be a devastating condition that forms after craniectomy. ...
PRIMARY OBJECTIVES:. I. To screen cancer patients across different histological sites to identify those with functional defects in the Fanconi anemia (FA) pathway in their tumors.. II. To establish the safety and practicality of treating patients with FA deficient tumors with the poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor ABT-888 (veliparib) as protracted monotherapy.. III. To establish the safety and practicality of treating patients with FA deficient tumors with the combination of mitomycin C (MMC) and ABT-888.. IV. To select a dose of ABT-888 protracted monotherapy and a dose-schedule of the combination of mitomycin C and ABT-888 in patients with FA deficient tumors for phase 2 trials.. SECONDARY OBJECTIVES:. I. To evaluate for germ-line FA repair deficiency and BRCA mutations in peripheral blood mononuclear (PBMC) in patients receiving ABT-888 treatment.. II. To evaluate in PBMC samples for foci produced by the histone variant gamma-H2A histone family, member X ...
PRIMARY OBJECTIVES:. I. To screen cancer patients across different histological sites to identify those with functional defects in the Fanconi anemia (FA) pathway in their tumors.. II. To establish the safety and practicality of treating patients with FA deficient tumors with the poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor ABT-888 (veliparib) as protracted monotherapy.. III. To establish the safety and practicality of treating patients with FA deficient tumors with the combination of mitomycin C (MMC) and ABT-888.. IV. To select a dose of ABT-888 protracted monotherapy and a dose-schedule of the combination of mitomycin C and ABT-888 in patients with FA deficient tumors for phase 2 trials.. SECONDARY OBJECTIVES:. I. To evaluate for germ-line FA repair deficiency and BRCA mutations in peripheral blood mononuclear (PBMC) in patients receiving ABT-888 treatment.. II. To evaluate in PBMC samples for foci produced by the histone variant gamma-H2A histone family, member X ...
Mitomycin for injection by Hospira: Mitomycin belongs to the group of cancer-fighting medications known as antineoplastics, and specifically to the group of antineoplastics called actinomycins. Another actinomycin is dactinomycin.
ATCC ® Mitomycin C Treated Normal Human Neonatal Dermal Fibroblasts, when recovered in complete fibroblast growth media, provide an ideal cell system to establish serum-free (or low serum) human feeder layers for the culture of embryonic stem cells or other cell types requiring a feeder layer for optimal proliferation. The cells are cryopreserved in the second passage to ensure the highest viability and plating efficiency. ATCC ® Primary Cell Solutions cells, media, supplements and reagents are quality tested together to guarantee optimum performance and reliability.
View and buy high purity Mitomycin C from Tocris Bioscience, the leading worldwide supplier of high performance life science reagents.
Buy this product (CAS 50-07-7), a DNA crosslinking agent that inhibits DNA synthesis, induces apoptosis in a variety of cells, and activates caspase, from Santa Cruz. Purity: ≥99%
Detailed drug Information for mitomycin Intravenous. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
When adminstering mitomycin intravesically to patients; I draw it up in a 60-cc syringe and then I have someone else assist to pour the solution into a catheter syringe after I catheterize the
The national download ivor hortons beginning visual c going in Skyline for protein digestion tribe had extracted to 10,000 for TripleTOF 5600 minutes and to 30,000 for TripleTOF 6600 roles. cross-validation download ivor hortons beginning visual c of cheerful previous Administrative substrates progress E. 02212; interrogation group, turned nt inspired in 3 performance condenses. Prestigious to the download ivor hortons beginning visual c plus plus of dark algorithms, 3 breast is for each value should see for wrong father in environment to say not scientific potential countries between the regulatory chromatograms.
Learn about PeroXX 105C Plus for animal usage including: active ingredients, directions for use, precautions, and storage information.
Inaccessibility of medications to poorly vascularized strata of tumor is among the limiting elements in tumor therapy. RT-PCR for FasL mRNA. THP-1 M had been treated with indicated concentrations of MMC, and prepared for RT-PCR. in the rules of FasL manifestation. (i) Traditional western blot evaluation of PPARin MMC-treated cells. HeLa, SiHa and THP-1 M […]. ...
Evaluation of selected antitumor agents as subversive substrate and potential inhibitor of trypanothione reductase: an alternative approach for chemotherapy of ...
Dorp, F.; Eisenhardt, A.; Goebell, P.-J.; Gschwend, J.; Jakse, G.; Jäger, T.; Jocham, D.; Karl, A.; Knüchel Clarke, R.; Krege, S.; Lümmen, G.; Ohlmann, C.; Olbricht, T.; Otto, T.; Rettenmeier, A.; Rübben, H.; Schenck, M.; Schmid, K.W.; Stief, C.; Stöckle, M.; Tritschler, S ...
I have to say, just that simple for-loop is a prime example of why I dont like C++.. I can memorise the entire standard library of C, and every command in it, and every operator, and every syntax. Nobody can then run up a piece of code which cant be deciphered (sure, I may have to play pre-processor games, but everything will come down to obvious code).. When there are a dozen ways to iterate over a simple group of objects, and half-a-dozen different groups of objects, and obscure syntactic sugar the people use because it saves them a fraction of a second, it quickly becomes a pain to understand. Which means its a pain to verify. Which means its a pain to secure. Which is not what you want in something like C/C++.. The hidden effects of such code, where things are iterated upon, objects are instantiated, etc. behind your back is a real pain to me. Its like every simple line becoming a dozen subroutines, overrode and silently inserted, and no obvious way to tell thats whats happening ...
These cells are to be used as feeder cells to support the growth of other cells. They have been treated with Mitomycin C and will not replicate.
Pulsatron Pump LD02SA-VTC1-U03 - C Plus (C+) Series Chemical Metering Pumps from Pulsafeeder are in Stock at www.PumpCatalog.com - Click to Order!
Pulsatron Pump LD02S2-PHC1-O07 - C Plus (C+) Series Chemical Metering Pumps from Pulsafeeder are in Stock at www.PumpCatalog.com - Click to Order!
MMC TV LAŠKO. MMC TV Laško je spletna televizija, ki v lokalnem okolju deluje od leta 2011. V letu 2015 smo posodobili našo spletno stran, ki ponuja večjo preglednost in dostopnost medijskih vsebin. Priprava prispevkov in oddaj na lokalni ravni oziroma o lokalnem dogajanju je pomembna za raznolikost medijskih vsebin v Sloveniji in predvsem za enakopravno uresničevanje pravice tudi lokalnega in regionalnega prebivalstva do javnega obveščanja ter objektivne obveščenosti.. Občina Laško je ena največjih občin v Sloveniji, kar pomeni veliko število dogodkov, dejavnosti in tudi problematike v mestu in okoliških krajih. Dogajanje v občini je večkrat povezano tudi z ohranjanjem tradicij in slovenske kulture, pri čemer ste najbolj dejavni predvsem lokalna društva in organizacije, v občini se večkrat pojavlja problematika varstva pred naravnimi nesrečami, mnogo je gospodarskih subjektov, navsezadnje pa se v naši občini skriva veliko posameznikov z zgodbami, izkušnjami in predlogi, ...
Pre- and intraoperative mitomycin C for recurrent pterygium associated with symblepharon Isyaku MohammedDepartment of Ophthalmology, Aminu Kano Teaching Hospital, Kano, NigeriaBackground: Treatment of recurrent pterygium associated with symblepharon usually involves the use of tissue grafting and/or the intraoperative application of mitomycin C (MMC). For the graft, a conjunctival/limbal autograft and/or amniotic membrane may be used. This generally requires extra technical skills and assistance, an increase in the cost and duration of surgery, and a more extensive anesthesia (a complete eye block or general anesthesia). Although widely used, safety concerns have been raised over MMC in the treatment of pterygia.Objective: The objective of this case report is to report the successful use of preoperative subconjunctival injection of low-dose (0.02%) MMC one month before bare sclera excision of a multirecurrent pterygium, as well as the concomitant intraoperative application of MMC to the conjunctival
Semantic Scholar extracted view of Abnormal sequence distribution in DNA synthesized by isolated nuclei from normal or mitomycin C-treated HeLa cells. by Masamichi Yamada et al.
Solid neoplasms may contain deficient or poorly functional vascular beds, a property that leads to the formation of hypoxic tumor cells, which form a therapeutically resistant cell population within the tumor that is difficult to eradicate by ionizing irradiation and most existing chemotherapeutic agents. As an approach to the therapeutic attack of hypoxic cells, we have measured the cytotoxicity and DNA lesions produced by the bioreductive alkylating agents mitomycin C and porfiromycin, two structurally similar antibiotics, in oxygen-deficient and aerobic cells. Mitomycin C and porfiromycin were preferentially cytotoxic to hypoxic EMT6 cells in culture, with porfiromycin producing a greater differential kill of hypoxic EMT6 cells relative to their oxygenated counterparts than did mitomycin C. Chinese hamster ovary cells were more resistant to these quinone antibiotics; although in this cell line, porfiromycin was significantly more cytotoxic to hypoxic cells than to aerobic cells, and the ...
The optimal treatment of tracheal stenosis remains undefined. Traditionally, tracheal stenosis has been managed by thoracic and othorhinolaryngology surgeons. Endoscopic procedures are usually performed as a bridge to definitive surgical intervention. With the development of interventional pulmonology field in the last 20 years, definitive management of tracheal stenosis using minimally invasive endoscopic methods became a possibility. Collaboration between pulmonologists and surgeons has become increasingly important to help define the best method of management for these patients.. Endoscopic treatment had been shown to be useful, especially in patients who are deemed high risk and too unwell for reconstructive surgery. One of the main drawbacks of endoscopic treatment and surgery is the risk of recurrence of trachea stenosis due to granulation and fibrotic tissue. Studies have shown that most of the recurrence of tracheal stenosis occurs within one to three months after the procedure [12, 14], ...
Purpose To analyze conjunctival cytological features 1 month after pterygium excision using limbo-conjunctival autograft (LCA) with and without intraoperative mitomycin C and to assess tissue short-term evolution in both situations.; Methods Fifty-nine primary nasal pterygia from 59 patients were excised with LCA. Twenty-nine were treated with intraoperative mitomycin C 0.02% (MMC+) and 30 were treated without it (MMC-). Impression cytology was performed in nasal and temporal conjunctiva before and 1 month after the excision. Goblet cell density (GCD) and nucleus-to-cytoplasm nongoblet epithelial cell ratio were quantified.; Results Surgical strategy comparisons (intergroup comparisons): All the preoperative data were, in mean, within the reference range, except for a slight goblet cell hyperplasia in the area of the lesion in MMC+ but no significant differences were found between the groups (p = 0.079 for GCD and p = 0.245 for nucleus-to-cytoplasm ratio; analysis of variance). Clinically ...
To the editor: Orwoll and others (1) have reported in the September issue on the association of mitomycin with interstitial pneumonia. In the past 2 years we have seen two patients who died with unexplained severe interstitial pneumonitis after receiving mitomycin chemotherapy.. The first case was that of a 53-year-old man with adenocarcinoma of the pancreas who received weekly mitomycin, 5-fluorouracil, and cytosine arabinoside during an 18-week period for a total mitomycin dose of 50 mg. He developed progressive dyspnea leading to death within 3 weeks after a short preterminal period of progressive dyspnea. At autopsy, alveolar septal thickening and ...
TY - JOUR. T1 - Bleb needling with mitomycin C as adjunctive therapy in failing blebs. T2 - A retrospective study. AU - Del Noce, Chiara. AU - Vagge, Aldo. AU - Traverso, Carlo Enrico. PY - 2019/6/1. Y1 - 2019/6/1. N2 - Purpose: To evaluate the effects and complications related to use of mitomycin C (MMC) as an adjunctive therapy in bleb needling. Methods: Retrospective review of the records of patients affected by open-angle glaucoma who underwent a bleb revision as a treatment for failed trabeculectomy. All subjects underwent surgery with a fornix-based approach to incision. Full baseline data for each patient included a comprehensive ocular and medical history, the patients Snellen visual acuity test results, and Goldmann applanation tonometry test results. Data were reported following observations occurring at 6, 12, 18, 24, and 30 months. In addition, the number and timing of needling with or without MMC subconjunctival injections and any short- and long-term complications were observed. ...
The SOS response to DNA damage that induces up to 10% of the prokaryotic genome requires RecA action to relieve LexA transcriptional repression. In Acinetobacter species, which lack LexA, the error-prone polymerase accessory UmuDAb is instead required for ddrR induction after DNA damage, suggesting it might be a LexA analog. RNA-Seq experiments defined the DNA damage transcriptome (mitomycin C-induced) of wild type, recA and umuDAb mutant strains of both A. baylyi ADP1 and A. baumannii ATCC 17978. Of the typical SOS response genes, few were differentially regulated in these species; many were repressed or absent. A striking 38.4% of all ADP1 genes, and 11.4% of all 17978 genes, were repressed under these conditions. In A. baylyi ADP1, 66 genes (2.0% of the genome), including a CRISPR/Cas system, were DNA damageinduced, and belonged to four regulons defined by differential use of recA and umuDAb. In A. baumannii ATCC 17978, however, induction of 99% of the 152 mitomycin C-induced genes depended on recA,
Mitomycin C (MMC), a known cytotoxic agent, requires cellular enzyme-mediated activation for effective antitumor activity. To study the bioreductive enzymes responsible for MMC activation in tumor cells, we examined the enzyme activities of DT-diaphorase (DTD) and NADPH: cytochrome P-450 reductase in 13 colon and gastric carcinoma cell lines and then compared these activities to the respective cellular MMC sensitivity. We found that cell lines with nonexistent or marginal DTD activity, such as St-4 and MKN7, showed resistance to MMC, in comparison to cell lines with DTD activity ranging from 210 to 1420 nmol/min/mg protein. No correlation was found between NADPH:cytochrome P-450 reductase activity and MMC sensitivity in these cell lines. To confirm the role of DTD in cellular MMC sensitivity, we constructed an expression vector containing NQO1, a gene that codes for DTD, and transfected the vector into St-4 cells expressing no DTD activity. Several transfectant clones with DTD activity from 144 ...
Whole transcriptome analyses have revealed a large number of novel transcripts including long and short noncoding RNAs (ncRNAs). Currently, there is great interest in characterizing the functions of the different classes of ncRNAs and their relevance to cellular processes. In particular, nuclear long ncRNAs may be involved in controlling various aspects of biological regulation, such as stress responses. By a combination of bioinformatic and experimental approaches, we identified 25 novel nuclear long ncRNAs from 6,088,565 full-length human cDNA sequences. Some nuclear long ncRNAs were conserved among vertebrates, whereas others were found only among primates. Expression profiling of the nuclear long ncRNAs in human tissues revealed that most were expressed ubiquitously. A subset of the identified nuclear long ncRNAs was induced by the genotoxic agents mitomycin C or doxorubicin, in HeLa Tet-off cells. There were no commonly altered nuclear long ncRNAs between mitomycin C- and doxorubicin-treated cells.
TY - JOUR. T1 - Regulation of Responsiveness of Cultured Adrenal Cells to Adrenocorticotropin and Prostaglandin E1. T2 - Cell Density, Cell Division, and Inhibitors of Protein Synthesis. AU - Hornsby, Peter J.. AU - Gill, Gordon N.. PY - 1981/1. Y1 - 1981/1. N2 - In cultured bovine adrenocortical cells, responsiveness to ACTH, as assessed by the maximal rate of ACTHstimulated cAMP production, has been found to depend on cell density and cell proliferation, while the maximal rate of prostaglandin E1, (PGE1)-stimulated cAMP production was constant.The combination of low cell density and normal cell proliferation caused a specific decline in responsiveness to ACTH. Responsiveness did not decline at any density when proliferation was inhibited by mitomycin C treatment. Specific declines in responsiveness to ACTH were also seen when cultures were treated with cycloheximide or sodium butyrate. When protein synthesis was completely inhibited by cycloheximide treatment, responsiveness to ACTH declined ...
Trade Name: Mutamycin®. How is this drug used? Mitomycin is FDA approved for the treatment of advanced stomach and pancreatic cancer in combination with other agents. It is important for patients to remember that physicians have the ability to prescribe medication for conditions other than those for which the drug has been approved by the FDA. Patients who have received a prescription of this drug for a condition other than which it is approved may wish to discuss this issue with their physician.. What is the mechanism of action? Mitomycin belongs to a class of agents called antitumor antibiotics. An antitumor antibiotic produces its anti-cancer effects by binding to DNA and inhibiting the production of proteins necessary for sustaining the life of a cell.. How is mitomycin given (administered)? Mitomycin may be administered into a vein (intravenous) and the dose depends on several factors, including the condition being treated, the size of the patient, the particular treatment regimen being ...
Cisplatin is a crucial agent in the treatment of many solid tumors, yet many tumors have either acquired or intrinsic resistance to the drug. We have used the homozygous diploid deletion pool of Saccharomyces cerevisiae, containing 4728 strains with individual deletion of all nonessential genes, to systematically identify genes that when deleted confer sensitivity to the anticancer agents cisplatin, oxaliplatin, and mitomycin C. We found that deletions of genes involved in nucleotide excision repair, recombinational repair, postreplication repair including translesional synthesis, and DNA interstrand cross-link repair resulted in sensitivity to all three of the agents, although with some differences between the platinum drugs and mitomycin C in the spectrum of required translesional polymerases. Putative defective repair of oxidative damage (imp2Delta strain) also resulted in sensitivity to platinum and oxaliplatin, but not to mitomycin C. Surprisingly in light of their different profiles of ...
Enediyne antibiotics have been reported to be the most potent cytotoxic antitumor agents. The pathway by which these compounds cleave DNA and induce apoptosis of tumor cells may be different from the caspase-mediated pathways that initiate typical apoptosis. In this report, we studied the apoptosis induced by lidamycin (LDM), a member of the enediyne antibiotic family, and compared the characteristics of LDM-induced apoptosis with those of typical apoptosis induced by mitomycin C or etoposide. Chromatin condensation occurred very rapidly and appeared as speckles in human hepatoma BEL-7402 and breast carcinoma MCF-7 cells after treatment with I muM LDM. In addition, co-staining the cells with the mitochondria-specific dye Mitosensor(TM) and the DNA-specific dye Hoechst 33342 enabled the visualization of mitochondria in normal control and LDM-treated cells but not in mitomycin C-treated cells. Neither the caspase inhibitor VAD-fmk nor the caspase-3 inhibitor DEVD-fmk was able to inhibit the DNA ...
Rarely, lju.oyhd.lugubre.org.jcq.bw malocclusion [URL=http://littlebackpackbigworld.com/product/cifran-od/ - cifran od[/URL - [URL=http://carlasmith2017.com/mitomycin/ - mitomycin[/URL - [URL=http://carlasmith2017.com/restasis-eye-drops/ - restasis eye drops generic[/URL - [URL=http://passagesinthevoid.com/furosemide/ - furosemide[/URL - [URL=http://frankfortamerican.com/zovirax/ - zovirax[/URL - radiopaque inflating cheapest cifran od purchase mitomycin restasis eye drops restasis eye drops online pharmacy furosemide zovirax online pharmacy develops mouth; spectacles; http://littlebackpackbigworld.com/product/cifran-od/ low cost cifran od cifran od http://carlasmith2017.com/mitomycin/ purchase mitomycin http://carlasmith2017.com/restasis-eye-drops/ generic restasis eye drops from india http://passagesinthevoid.com/furosemide/ furosemide http://frankfortamerican.com/zovirax/ zovirax coupon deformed opened ignored.. ...
A prospective randomized trial comparing streptozotocin, mitomycin C, and 5-FU (SMF) with mitomycin C and 5-FU (MF) in patients with advanced pancreatic cancer was performed. In patients with measurable disease the response rates were 34% (19/56) to SMF, and 8% (5/60) to MF (P = 0.009). Median survivals were similar, however, 18 versus 17 weeks (P = 0.356). Median survival of patients responding to chemotherapy was 33 weeks, and for nonresponders it was 17 weeks (P = 0.002). In patients with nonmeasurable disease, median survivals were 21 weeks (SMF) and 18 weeks (MF) (P = 0.797). Patients surviving greater than or equal to 48 weeks, however, appeared to be increased in the SMF arm (14 patients) compared to the MF (7 patients). Toxicity was moderate for both regimens, with SMF having greater gastrointestinal and renal toxicity. Chemotherapy with SMF appears to produce objective responses in patients with pancreatic cancer, but does not improve survival compared to MF ...
A prospective randomized trial comparing streptozotocin, mitomycin C, and 5-FU (SMF) with mitomycin C and 5-FU (MF) in patients with advanced pancreatic cancer was performed. In patients with measurable disease the response rates were 34% (19/56) to SMF, and 8% (5/60) to MF (P = 0.009). Median survivals were similar, however, 18 versus 17 weeks (P = 0.356). Median survival of patients responding to chemotherapy was 33 weeks, and for nonresponders it was 17 weeks (P = 0.002). In patients with nonmeasurable disease, median survivals were 21 weeks (SMF) and 18 weeks (MF) (P = 0.797). Patients surviving greater than or equal to 48 weeks, however, appeared to be increased in the SMF arm (14 patients) compared to the MF (7 patients). Toxicity was moderate for both regimens, with SMF having greater gastrointestinal and renal toxicity. Chemotherapy with SMF appears to produce objective responses in patients with pancreatic cancer, but does not improve survival compared to MF ...
Fanconi anemia (FA) is a rare, recessive, genetically heterogeneous, chromosomal instability disorder, characterized by developmental abnormalities, retarded growth, bone marrow failure, and a high risk for the development of cancer (Auerbach et al. 2001; Alter 2003; Rosenberg et al. 2003; Kutler et al. 2003). Fanconi anemia patient-derived cells are extremely sensitive to bifunctional alkylating or DNA interstrand cross-linking agents, such as mitomycin C and cisplatin (Ishida and Buchwald 1982; Wang 2007).. Currently, sixteen FA genes have been identified, each corresponding to a distinct complementation group: FA-A, -B, -C, -D1, -D2, -E, -F, -G, -I, -J, -L, -M, -N, -O, -P, and -Q (Strathdee et al. 1992; Pronk et al. 1995; Apostolou et al. 1996; Lo Ten Foe et al. 1996; de Winter et al. 1998, 2000a, b; Waisfisz et al. 1999; Timmers et al. 2001; Howlett et al. 2002; Meetei et al. 2003, 2004, 2005; Levitus et al. 2005; Levran et al. 2005a; Dorsman et al. 2007; Xia et al. 2007; Smogorzewska et ...
In this study we provide a comprehensive clinical characterization of a cohort of patients with newly diagnosed anal carcinoma. According to our analyses, clinical symptoms have predictive value for local staging of anal carcinoma.. Our study fills a gap in our knowledge since no systematic study regarding physical findings in anal carcinoma has been performed. Furthermore, no contemporary study describing the clinical presentation of anal carcinoma is available and the incidence of anal carcinoma, the prevalence of risk factors and medical practice has tremendously changed since the publication of the last paper characterizing anal carcinoma almost 30 years ago [10-14]. In agreement with previous studies, bleeding, anal pain and sensation of an anal mass remain the most frequent symptoms of anal carcinoma. However, the presence of anal pain including painful defecation and perianal pain (63 vs. 20-35 %) as well as anal bleeding (77 vs. 45 %) were more frequent than in historical studies ...
Conventional chemotherapy for unresectable or metastatic adenocarcinoma of the pancreas has had little effect on palliation or survival. Almost all studies of systemic therapy have involved empiric use of a variety of Phase II or conventional agents alone or in combination. On the basis of recent studies using a human tumor pancreatic cancer (PC) xenograft in nude mice, a Phase I clinical trial of cisplatin, high-dose cytosine arabinoside (Ara-C), and caffeine (CAC) was performed in patients with advanced incurable PC. A tolerable dose and schedule of the three agents were developed. Seven of 18 patients with measurable disease in this Phase I trial had partial responses to CAC. A Phase III comparison of CAC versus standard treatment using streptozotocin, mitomycin, and 5-fluorouracil (SMF) was performed. Eighty-two patients with advanced PC were entered into this random assignment trial. The two treatment arms were well balanced for the usual prognostic factors. Although the acute (e.g., nausea ...
The p53 tumor suppressor protein has been implicated as a mediator of programmed cell death (PCD). A series of nontransformed mammary epithelial cell (MEC) lines were used to correlate p53 function with activation of PCD. Treatment of MECs expressing mutant, inactive, or no p53 with DNA-damaging agents did not induce apoptosis. Upon introduction of temperature-sensitive p53 into HC11 cells, which lack wild-type (wt) p53, PCD was observed after mitomycin treatment at 32 degrees, when the ts p53 protein is in wt conformation. Thus, wt p53 mediates activation of PCD in response to mitomycin in HC11 cells. Treatment of the MCF10-A cells, which express wt p53, with various DNA-damaging agents led to nuclear accumulation of p53. Only mitomycin treatment led to an increase in the number of apoptotic nuclei. ErbB-2-transformed MCF10-A cells responded to mitomycin, cisplatin, and 5-Fl-uracil, suggesting that signaling from activated ErbB-2 enhances the cells ability to respond to DNA damage. A ...
Toxic antibiotic of the mitomycin group, obtained from MITOMYCIN and also from Streptomyces ardus and other species. It is proposed as an antineoplastic agent, with some antibiotic properties ...
Background Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide that is particularly refractory to chemotherapy. Several studies have proposed combination chemotherapy regimen...
UCN-01 (7-hydroxy-staurosporine) is a potent and selective inhibitor of protein kinase C (PKC), one of several protein kinases examined. UCN-01 itself was shown to exhibit antitumor activity in vitro and in vivo in oncogene-activated human and murine tumor cell lines. Since the mechanism(s) of actio …
I have recently been diagnosed with hemoraghic interstitial cystitis, and I only had one treatment right after TURBT in 9/2012. This was done to me without my...
Sigma-Aldrich offers abstracts and full-text articles by [Laura Kahmann, Ulrich Beyer, Grit Mehlhorn, Falk C Thiel, Vratislav Strnad, Peter A Fasching, Michael P Lux].
Chemical Entities of Biological Interest (ChEBI) is a freely available dictionary of molecular entities focused on small chemical compounds.
Another name for Anal Carcinoma is Anal Cancer. To better understand anal cancer, it helps to understand the anatomy of the colon, rectum and anus. The ...
OncoLink, the Webs first cancer resource,provides comprehensive information on coping with cancer, cancer treatments, cancer research advances, continuing medical education, cancer prevention, and clinical trials
Logical Images, Inc. d/b/a VisualDx (hereinafter VisualDx, we, us, or our) has created this Acceptable Use Policy, Medical Disclaimer, & Copyright Notice (this Notice) to inform you (hereinafter you, your, or yourself) as a purchaser of a license for and/or user of the software hosted by VisualDx known as VisualDx (the Software) of certain important terms and conditions set forth in the VisualDx End User License Agreement that governs your license for and/or use of the Software (the EULA). This Notice is subject to all of the terms and conditions set forth in the EULA and does not replace or limit it in anyway. You should read the EULA in detail prior to purchasing a license for or using the Software to make sure you understand and agree to its terms and conditions. Nothing in this Notice will (a) expand your rights or VisualDx′s obligations under the EULA or (b) modify or otherwise affect any terms and conditions of the EULA or the rights of the parties under the EULA. In ...
I was hanging out at Jamies house on April 8th - watching the Voice, playing Battleship with the kids like any other night. I left her house late that night knowing I would see her in the morning at our 32 week, 5 day appointment/ultrasound. We were both so excited to see how much these babies weighed and make sure everything was still going great. The next morning I woke up at 4:48am to my phone vibrating. I see a call from Jamie Dabo and my heart started racing. I think I was still somewhere between a dream and reality when I hear, Um...my water just broke. I immediately jumped out of bed, flipped on the lights and said, Ok, Ill meet you at the hospital. Jamie said she was doing fine and she was going to get ready really quick and pack a bag. I told her to text me when she left for the hospital and I would meet her there. As soon as we hung up I called Curtis and woke him up with, Jamies water just broke! I thought for sure they would be able to stop delivery for at least 24 hours so ...
Xiao Yu Wu is the author of this article in the Journal of Visualized Experiments: Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
The standard treatment for anal cancer is a combination of chemotherapy (typically with 5-FU and mitomycin) and radiation. This has been the standard of care for well over a decade. In general,...
I really didnt want to be posting this type of post in the group. I know it leads to a lot of worry for you mommas but I also feel like I need to acknowledge it as well. Went in today for my first u/s at 7w5d and she couldnt see anything with the abdominal u/s so she had me empty my bladder and we did the t/v u/s. We could see the sac but only a yolk sac -an oversized one at that and no fetal pole or anything. :( So guess it was a blighted ovum. She didnt actually use that term, she just called it a MMC. She gave me the option of a dnc or waiting it out. Not sure quite yet, I had a dnc in Aug 2009 after a MMC at 10 wk ( baby measured 8.5). This time, no baby! I had symptoms like fatigue and sore breasts but no major nausea and no vomiting. Im so thankful to have my healthy 3 yr old and will give her lots of extra hugs tonight. Best of luck to you ladies. I hope you have a healthy and happy 9 months and wishing you all adorable and gorgeous babies! Hopefully I can get to trying again in just a few
Hi ladies, I just wanted to ask if any of you ladies have experienced a MMC where the uterus continued to grow? And can somebody tell me why this happens??? Is it common etc?? Thanking you in advance
Do you really want to delete this prezi? Neither you, nor the coeditors you shared it with will be able to recover it again. DeleteCancel ...
Allen, G.; Pidacks, C.; Weiss, M. (5 June 1996). "The Mitomycin Antibiotics. Synthetic Studies". J. Am. Chem. Soc. 88 (11): ...
The additional use of mitomycin C is of unclear effect. Radiotherapy has also be used in an attempt to reduce the risk of ... CS1 maint: Multiple names: authors list (link) Martins, TG; Costa, AL; Alves, MR; Chammas, R; Schor, P (2016). "Mitomycin C in ...
Mitomycin C in Congenital Glaucoma. Ophthalmic Surgery 1997; 28:979-85. 212. Honavar SG, Sekhar GC, Goyal M, Jalali S, Madhavi ...
... and mitomycin". Chemical Reviews. 105 (2): 739-58. doi:10.1021/cr030117g. PMID 15700963. Zhang, C; Griffith, BR; Fu, Q; ...
Mitomycin is a cytotoxic antibiotic with the ability to alkylate DNA. Most chemotherapy is delivered intravenously, although a ... Verweij J, Pinedo HM (Oct 1990). "Mitomycin C: mechanism of action, usefulness and limitations". Anti-Cancer Drugs. 1 (1): 5-13 ... The most important subgroup is the anthracyclines and the bleomycins; other prominent examples include mitomycin C, ... mitomycin C, anthracyclines, BCNU, melphalan) including CDDP could be reversed at least partially by the addition of heat. ...
doi:10.1007/s10600-015-1296-6. Wolf, Gudrun; Wörth, Jürgen; Achenbach, Hans (1975). "Mitomycin und ein neues Phenoxazon-Pigment ... Streptomyces michiganensis produces actinomycin X, antipain and mitomycin. Xue, Jinghua; Wu, Min (27 March 2015). "Cyclic ... "Mitomycin und ein neues Phenoxazon-Pigment aus Streptomyces michiganensis". Archives of Microbiology. 106 (3): 245-249. doi: ...
Other cytotoxic antibiotics are anthracyclines, mitomycin C, bleomycin, mithramycin. Antibodies are sometimes used as a quick ...
Marey, H M; S S Mandour; A F Ellakwa (Oct 2012). "Subscleral Trabeculectomy with Mitomycin-C Versus Ologen for Treatment of ... "A prospective randomised trial of trabeculectomy using mitomycin C vs an ologen implant in open angle glaucoma". Eye. 24 (9): ... "Biodegradable collagen matrix implant vs mitomycin-C as an adjuvant in trabeculectomy: a 24-month, randomized clinical trial". ... is created under the conjunctiva and Tenon's capsule and the wound bed is treated for several seconds to minutes with mitomycin ...
Cabourne, Emily; Clarke, Jonathan C. K.; Schlottmann, Patricio G.; Evans, Jennifer R. (2015-11-06). "Mitomycin C versus 5- ...
Kersey, J. P.; Vivian, A. J. (Jul-Sep 2008). "Mitomycin and amniotic membrane: a new method of reducing adhesions and fibrosis ... Fibrosis can be reduced by use of mitomycin C during surgery. A relatively new method, primarily devised by Swiss ...
These polymorphisms may have differential effects on platinum and mitomycin damage. ERCC1 protein expression is reduced or ...
26(1):95-7. Min JK, Kee CW, Sohn SW, Lee HJ, Woo JM, Yim JH (2013). Surgical outcome of mitomycin C-soaked collagen matrix ...
Min JK, Kee CW, Sohn SW, Lee HJ, Woo JM, Yim JH (2013). Surgical outcome of mitomycin C-soaked collagen matrix implant in ... Compared with Mitomycin C for Treatment of Primary Open-Angle Glaucoma: Results at 5 Years. J Ophthalmol. 2015:637537. ...
Mitomycin C is the most commonly used agent because it was one of the first used drugs for this therapy and less expensive than ... Mitomycin C30 mg in 3L for 60min + 10 mg for 40min OxaliplatinGiven bidirectionally with 5-FU intravenously and oxalplatin in ... The chemotherapeutic agents generally infused during IPHC are mitomycin-C and cisplatin. IPHC is generally used after surgical ...
Holliday R (1964). "The induction of mitotic recombination by mitomycin C in Ustilago and Saccharomyces". Genetics. 50 (3): 325 ...
Some methods prompt production with UV radiation, Mitomycin C, or heat shock. UV radiation and Mitomycin C are used because the ... Saito H, Watanabe T, Osasa S, Tado O (1979). "Susceptibility of normal and tumor cells to mycobacteriocin and mitomycin C". ...
... , involved in Fanconi anemia, confers resistance to both hygromycin B and mitomycin C. FANCG contains a 5-prime GC-rich ... Kruyt FA, Abou-Zahr F, Mok H, Youssoufian H (1999). "Resistance to mitomycin C requires direct interaction between the Fanconi ... Kruyt FA, Abou-Zahr F, Mok H, Youssoufian H (November 1999). "Resistance to mitomycin C requires direct interaction between the ... "Reduced fertility and hypersensitivity to mitomycin C characterize Fancg/Xrcc9 null mice". Hum. Mol. Genet. 11 (3): 273-81. doi ...
It produces chemotherapeutic drug mitomycin C. http://www.uniprot.org/taxonomy/53502. ...
Cillino, S; Casuccio A; Di Pace F; Cagini C; Ferraro LL (Mar 2016). "Biodegradable collagen matrix implant versus mitomycin-C ... Yuan, F; Li, L; Chen; Yan; Wang (2015). "Biodegradable 3D-Porous Collagen Matrix (Ologen) Compared with Mitomycin C for ... Traditionally, chemotherapeutic adjuvants, such as mitomycin C (MMC) or 5-fluorouracil (5-FU), are applied with soaked sponges ... This may require preventive measures using antifibrotic medications, such as 5-fluorouracil or mitomycin-C (during the ...
Mitomycins and porfiromycin: chemical mechanism of activation and cross-linking of DNA. Science. 145:55-56. August PR, Rahn JA ... Inducible synthesis of Mitomycin C resistance gene product (MCRA) from Streptomyces lavendulae. Gene: An International Journal ... Mitomycin Resistance in Streptomyces lavendulae Includes a Novel Drug-Binding-Protein-Dependent Export System. Journal of ... Characterization of a Mitomycin-Binding Drug Resistance Mechanism from the Producing Organism, Streptomyces lavendulae. Journal ...
Competence in S. pneumoniae is induced by DNA-damaging agents such as mitomycin C, fluoroquinolone antibiotics (norfloxacin, ... Transformation protects S. pneumoniae against the bactericidal effect of mitomycin C. Michod et al. summarized evidence that ...
You JS, Hau DM, Chen KT, Huang HF (1994). "Combined effects of chuling (Polyporus umbellatus) extract and mitomycin C on ...
1994). "p56/p53lyn tyrosine kinase activation in mammalian cells treated with mitomycin C". Oncogene. 9 (10): 3005-11. PMID ...
PVOD has also been associated with several chemotherapy regimens such as bleomycin, BCNU, and mitomycin. Chloe Temtchine, ...
April 2009). "Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the ... Alfred Witjes J, Hendricksen K, Gofrit O, Risi O, Nativ O (June 2009). "Intravesical hyperthermia and mitomycin-C for carcinoma ... Di Stasi SM, Riedl C (June 2009). "Updates in intravesical electromotive drug administration of mitomycin-C for non-muscle ...
Mitomycin C can only act as a crosslinker when a DNA nucleotide has had a reduction to its quinone ring. When two dG's have ... Mitomycin C (MMC) is from a class of antibiotics that are used broadly in chemotherapy, often with gastrointestinal related ... Mitomycin also harbors the ability to form monoadducts and intrastrand crosslinks with DNA as well. The interstrand crosslinks ... of Mitomycin C are formed in the minor groove of DNA, inducing a moderate widening or stretching to the DNA helix in order to ...
2007). "Altered expression of FANCL confers mitomycin C sensitivity in Calu-6 lung cancer cells". Cancer Biol. Ther. 5 (12): ...
They are derived from the mitomycins by reduction and are the active alkylating agents responsible for the antitumor activity ... Iyengar, 1 Bhashyam S.; Remers, William A. (1985). "A comparison of mechanisms proposed for the conversion of mitomycins into ... of the mitomycins. Maliepaard, Marc; de Mol, Nico J.; Tomasz, Maria; Gargiulo, Dario; Janssen, Lambert H. M.; van Duynhoven, ...
... and polymerase eta-mediated error-prone removal of mitomycin C interstrand cross-links". Mol. Cell. Biol. 23 (2): 754-61. doi: ...
"Five-minute treatments with fluorouracil, floxuridine, and mitomycin have long-term effects on human Tenon's capsule ...
Mitomycin C is a mitomycin that is used as a chemotherapeutic agent by virtue of its antitumour activity. It is given ... Mitomycin is also used as a chemotherapeutic agent in glaucoma surgery. Kersey JP, Vivian AJ (Jul-Sep 2008). "Mitomycin and ... Mitomycin C is a potent DNA crosslinker. A single crosslink per genome has shown to be effective in killing bacteria. This is ... Mitomycin C has also been used topically rather than intravenously in several areas. The first is cancers, particularly bladder ...
When adminstering mitomycin intravesically to patients; I draw it up in a 60-cc syringe and then I have someone else assist to ... When adminstering mitomycin intravesically to patients; I draw it up in a 60-cc syringe and then I have someone else assist to ... is there anything like that for mitomycin tx? ...
Mitomycins. Mitomycin. Antibiotics, Antineoplastic. Antineoplastic Agents. Alkylating Agents. Molecular Mechanisms of ... Mitomycin-c Application for PRK. The safety and scientific validity of this study is the responsibility of the study sponsor ... Mitomycin-c Application for Photorefractive Keratectomy. Resource links provided by the National Library of Medicine ... Drug: mitomycin-C. Placebo Comparator: BSS group One eye of each patient was randomly assigned to receive balanced salt ...
Mitomycin C Treated Normal Human Neonatal Dermal Fibroblasts, when recovered in complete fibroblast growth media, provide an ... Primary Dermal Fibroblast; Normal, Human, Neonatal, Mitomycin C Treated (HDFn) (ATCC® PCS-201-011™) Organism: Homo sapiens, ... Primary Dermal Fibroblast; Normal, Human, Neonatal, Mitomycin C Treated (HDFn) ATCC® PCS-201-011™ frozen 1 mL ... Primary neonatal fibroblasts have been treated with mitomycin C at passage #1 and will not replicate. Once the feeder cells ...
Mitomycin belongs to the group of cancer-fighting medications known as antineoplastics, and specifically to the group of ... As well as interfering with the genetic material DNA of cancer cells, mitomycin can interfere with some of your normal cells. ... Kidney disease: Mitomycin may worsen kidney disease.. Pregnancy: Use of this medication by pregnant women has not been studied ... The recommended dose and dosing schedule of mitomycin varies according to the specific condition being treated, the response to ...
View and buy high purity Mitomycin C from Tocris Bioscience, the leading worldwide supplier of high performance life science ... Reviews for Mitomycin C. There are currently no reviews for this product. Be the first to review Mitomycin C and earn rewards! ... 2 Citations for Mitomycin C. Citations are publications that use Tocris products. Selected citations for Mitomycin C include: ... Have you used Mitomycin C?. Submit a review and receive an Amazon gift card.. $10US/$10CAN/€7/£6 gift card for a review without ...
Mitomycin C (CAS 50-07-7) Mitomycin C , CAS 50-07-7 is rated 5.0 out of 5 by 4. ... Rated 5 out of 5 by Hansini from I have used Mitomycin C for my experiments I have used Mitomycin C for my experiments and I am ... Mitomycin C Product Citations See how others have used Mitomycin C. Click on the entry to view the PubMed entry . ... Mitomycin C (CAS 50-07-7) is supplied as solid and we suggest storing this at -20°C. The product is warranted for up to one ...
mitomycin Cardiotoxicity of mitomycin A, mitomycin C, and seven. N. 7. analogs in vitro. Cardiotoxicity of mitomycin A, ... mitomycin Phase I study of mitomycin C and menadione in advanced solid tumors. Phase I study of mitomycin C and menadione in ... mitomycin Pharmacokinetics of mitomycin C in rabbit and human. Pharmacokinetics of mitomycin C in rabbit and human. Hazel, Guy ... mitomycin Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer. Docetaxel and mitomycin as ...
... mitomycin c intravesical Instillation. here in video we have instilled 40 mg of Mitomycin,.Mitomycin C is a mitomycin that is ... Plasma mitomycin C concentrations determined by HPLC coupled to.. Mitomycin Bladder Instillation. Mitomycin bladder ... Mitomycin (Injection). (About this - PubMed Health) Uses Uses of.Mitomycin medac is a medicine available in a number of ... Mitomycin can cause a severe decrease in the number of blood cells in your bone marrow.Mitomycin Instillations (treatment) ...
Topical application of mitomycin C may be a successful method of preventing epidural fibrosis following craniectomy. ... The authors conducted a study to determine the effectiveness of mitomycin C (MMC) in preventing epidural fibrosis in rats which ...
Chromosomal content of MN was characterized in human leukocytes treated with mitomycin C (MMC) and bleomycin (BLM) by FISH ... From: Comparative analysis of individual chromosome involvement in micronuclei induced by mitomycin C and bleomycin in human ...
A Phase III study comparing radiotherapy alone with radiotherapy plus Mitomycin C for cervix cancer has been completed in ... Venezuela with results showing a significant improvement in disease-free survival with the addition of Mitomycin C, which is a ...
They include mitomycin A, mitomycin B, and mitomycin C. When the name mitomycin occurs alone, it usually refers to mitomycin C ... Mitomycin C is used as a medicine for treating various disorders associated with the growth and spread of cells. In general, ... Mitomycin C is used to treat symptoms of pancreatic and stomach cancer, and is under clinical research for its potential to ... "Mitomycin". Drugs.com. 2017. Retrieved 11 November 2017. Rustagi, T; Aslanian, H. R; Laine, L (2015). "Treatment of Refractory ...
mitomycin (plural mitomycins). *(biochemistry) Any of a family of aziridine-containing natural products isolated from the ... Retrieved from "https://en.wiktionary.org/w/index.php?title=mitomycin&oldid=44962053" ...
Mitomycin: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before receiving mitomycin,. *tell your doctor and pharmacist if you are allergic to mitomycin, any other medications, or any ... Mitomycin comes as a powder to be mixed with liquid and injected intravenously (into a vein) by a doctor or nurse in a medical ... Mitomycin is a type of antibiotic that is only used in cancer chemotherapy. It slows or stops the growth of cancer cells in ...
... has role antineoplastic agent (CHEBI:35610) mitomycin C (CHEBI:27504) is a mitomycin (CHEBI:25357) ... CHEBI:27504 - mitomycin C. Main. ChEBI Ontology. Automatic Xrefs. Reactions. Pathways. Models. ... via mitomycin ). bacterial metabolite Any prokaryotic metabolite produced during a metabolic reaction in bacteria. ... mitomycin C (CHEBI:27504) has role alkylating agent (CHEBI:22333) ...
Mitomycin Pyelocalyceal: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before receiving mitomycin pyelocalyceal,. *tell your doctor and pharmacist if you are allergic to mitomycin, any other ... Mitomycin is in a class of medications called anthracenediones (anticancer antibiotics). Mitomycin pyelocalyceal treats cancer ... Mitomycin comes as a powder to be mixed with a gel solution and given through a catheter (a small flexible plastic tube) into ...
... injection contains the active ingredient mitomycin, which is a type of anticancer chemotherapy medicine ... Mitomycin C Kyowa. Mitomycin C Kyowa injection contains the active ingredient mitomycin, which is a type of anticancer ... Mitomycin works by stopping the cancer cells from growing and multiplying.. Mitomycin inserts itself into the strands of ... Mitomycin C Kyowa injection contains the active ingredient mitomycin, which is a type of anticancer chemotherapy medicine ...
A list of US medications equivalent to Mitomycin is available on the Drugs.com website. ... Mitomycin is a medicine available in a number of countries worldwide. ... Mitomycin. In the US, Mitomycin (mitomycin systemic) is a member of the drug class antibiotics/antineoplastics and is used to ... Mitomycin C Arrow. Actavis, New Zealand. *Mitomycin C Kyowa. Ebewe Pharma, Austria; Kyowa Hakko Kirin, China; Nordic Group, ...
Find out more about how it is given and possible side effects of mitomycin. ... Mitomycin is also known as Mitomycin C Kyowa®. It is used to treat many different types of cancer. ... What is mitomycin (Mitomycin C Kyowa®)?. Mitomycin (Mitomycin C Kyowa®) is a chemotherapy drug used to treat different cancers ... How mitomycin is given. You will be given mitomycin in the chemotherapy day unit or during a stay in hospital. A chemotherapy ...
... NSC365354 Mitomycin C analog
Advice and warnings for the use of Mitomycin ophthalmic (Mitosol) during pregnancy. FDA Pregnancy Category X - Not for use in ... Mitomycin ophthalmic Pregnancy and Breastfeeding Warnings. Mitomycin ophthalmic is also known as: Mitosol ... Mitomycin ophthalmic Breastfeeding Warnings. Use is not recommended and a decision should be made to discontinue breastfeeding ... Mitosol (mitoMYcin ophthalmic)." Mobius Therapeutics, St. Loius, MO. *United States National Library of Medicine "Toxnet. ...
Mitomycin (UNII: 50SG953SK6) (Mitomycin - UNII:50SG953SK6) Mitomycin. 0.2 mg in 1 mL. ... Mitomycin is cytotoxic. Use of mitomycin in concentrations higher than 0.2 mg/mL or use for longer than 2 minutes may lead to ... Mitomycin is cytotoxic. Use of mitomycin in concentrations higher than 0.2 mg/mL or use for longer than 2 minutes may lead to ... MITOSOL- mitomycin kit. To receive this label RSS feed. Copy the URL below and paste it into your RSS Reader application. https ...
Mitomycin (Mutamycin) chemotherapy side effects, how its given, how it works, precautions and self care tips for treatment of ... Mutamycin is the trade name for mitomycin. MTC and Mitomycin-C are other names for mitomycin. In some cases, health care ... There is no pill form of mitomycin. *The amount of mitomycin that you will receive depends on many factors, including your ... There is a maximum lifetime dose of mitomycin. Your health care professional will monitor the amount of mitomycin you receive ...
Mitomycin sometimes causes a temporary loss of hair. After treatment has ended, normal hair growth should return. ...
Mitomycin is usually given together with certain other medicines. If you are using a combination of medicines, it is important ...
Find patient medical information for Mitomycin Intravenous on WebMD including its uses, side effects and safety, interactions, ... mitomycin 20 mg intravenous solution. color. blue violet. shape. No data.. imprint. No data.. This medicine is a blue violet, ... mitomycin 40 mg intravenous solution. color. blue violet. shape. No data.. imprint. No data.. This medicine is a blue violet, ... mitomycin 40 mg intravenous solution. color. colorless. shape. No data.. imprint. No data.. This medicine is a colorless, clear ...
Mitomycin C (Ametycine, Mutamycin [MMC]; CAS No. 50-07-7), was studied. MMC, a documented animal teratogen, is an antibiotic ... To further characterize the Drosophila-based prescreen to detect developmental toxicants, Mitomycin C (Ametycine, Mutamycin [ ...
A MOLECULAR MECHANISM OF MITOMYCIN ACTION: LINKING OF COMPLEMENTARY DNA STRANDS Message Subject (Your Name) has sent you a ... A MOLECULAR MECHANISM OF MITOMYCIN ACTION: LINKING OF COMPLEMENTARY DNA STRANDS. V. N. Iyer and W. Szybalski ...
Mit-C information about active ingredients, pharmaceutical forms and doses, Mit-C indications, usages and related health products lists
Mitomycin C for glaucoma surgery. Surgical treatment of glaucoma is usually reserved for serious cases which cannot be ... Mitomycin C is a powerful agent which prevents scarring by inhibiting the multiplication of cells which produce scar tissue. ... The review found evidence that Mitomycin C reduces the risk of surgical failure in both high risk and primary surgery but no ... Mitomycin C versus 5-Fluorouracil for wound healing in glaucoma surgery. *Combined glaucoma and cataract surgery versus ...
... Timothy D. Lyon, Omar M. Ayyash, Matthew C ... "Bipolar Transurethral Incision of Bladder Neck Stenoses with Mitomycin C Injection," Advances in Urology, vol. 2015, Article ID ...
... Timothy D. Lyon, Omar M. Ayyash, Matthew C ... A. J. Vanni, L. N. Zinman, and J. C. Buckley, "Radial urethrotomy and intralesional mitomycin C for the management of recurrent ... B. Ferguson, S. D. Gray, and S. Thibeault, "Time and dose effects of mitomycin C on extracellular matrix fibroblasts and ... J. D. Redshaw, J. A. Broghammer, T. G. Smith et al., "Intralesional injection of mitomycin C at transurethral incision of ...
Mitomycin C in patients with gynecological malignancies.. [Laura Kahmann, Ulrich Beyer, Grit Mehlhorn, Falk C Thiel, Vratislav ... Mitomycin C (MMC) is an effective cytostatic agent used in the treatment of patients with gynecological malignancies and breast ... Mitomycin, European Pharmacopoeia (EP) Reference Standard C15H18N4O5 ...
2001). Functional enhancement of CFTR expression by mitomycin C. Cellular Physiology and Biochemistry, 11(2), 93-98. ... We report that mitomycin C (MMC) elicits such a response by increasing CFTR mRNA and protein expression in T-84 and HT-29 cells ...
... Authors: H.A. Alhadrami ... Keywords: SOS-lux biosensors, salmonella assay, in vitro digestion, mutagenicity, bioluminescent bacteria, Mitomycin C ...
Drug: Mitomycin -C Topical mitomycin-C at a dosage of 0.4mg/ml will be applied to cottonoid pledgets and placed into the radial ... Mitomycins. Mitomycin. Antibiotics, Antineoplastic. Antineoplastic Agents. Alkylating Agents. Molecular Mechanisms of ... Study of Mitomycin-C Application in Laryngotracheal Stenosis. This study is currently recruiting participants. See Contacts and ... Experimental: Mitomycin-C Patients will undergo standard endoscopic surgical treatment for LTS involving CO2 laser radial ...
Slavisa T, et al. A Definitive IMRT-SIB with concomitant chemotherapy for synchronous locally advanced anal canal cancer and prostate cancer. Case Reports in Oncological Medicine 2018: Jan 2018. Available from: URL: http://doi.org/10.1155/2018/6101759 - Austria ...
  • To evaluate the safety and efficacy of 5 seconds mitomycin-C (MMC) application during photorefractive keratectomy (PRK) for patients with low myopia. (clinicaltrials.gov)
  • The third is in esophageal and tracheal stenosis where application of mitomycin C onto the mucosa immediately following dilatation will decrease re-stenosis by decreasing the production of fibroblasts and scar tissue. (wikipedia.org)
  • Topical application of mitomycin C may be a successful method of preventing epidural fibrosis following craniectomy. (metu.edu.tr)
  • Primary neonatal fibroblasts have been treated with mitomycin C at passage #1 and will not replicate. (atcc.org)
  • The authors conducted a study to determine the effectiveness of mitomycin C (MMC) in preventing epidural fibrosis in rats which underwent craniectomy. (metu.edu.tr)
  • Bizanek et al (1992) Isolation and structure of an intrastrand cross-link adduct of mitomycin C and DNA. (tocris.com)
  • Mitomycin C has also been used topically rather than intravenously in several areas. (wikipedia.org)
  • Mitomycin C is a mitomycin that is used as a chemotherapeutic agent by virtue of its antitumour activity. (wikipedia.org)
  • Mammalian Cells treated with Mitomycin C (0.4 mg/mL for 5 min) can undergo apoptosis through upregulation of Bad, Fas, FasL and phosphorylated p53 along with activation of caspase-3, caspase-8, and caspase-9 activating both the intrinsic and extrinsic pathway for apoptosis. (scbt.com)
  • This is accomplished by reductive activation of mitomycin to form a mitosene, which reacts successively via N-alkylation of two DNA bases. (wikipedia.org)
  • mitomycin C has also been shown to reduce fibrosis in strabismus surgery. (wikipedia.org)
  • The effect of mitomycin C as fibrosis pr. (metu.edu.tr)
  • Be the first to review Mitomycin C and earn rewards! (tocris.com)
  • Mitomycin C is part of a family of azidine natural products. (scbt.com)
  • Mitomycin C is an alkylating agent used in cancer chemotherapy that shows some specificity towards hypoxic cells. (dundee.ac.uk)
  • The researchers treated 57 persons with stage I or II cancer of the esophagus and 33 persons with stage III or IV cancer of the esophagus with radiation therapy and chemotherapy with mitomycin. (cancerconnect.com)
  • 5-FU and mitomycin C were administrated 3 times every 4 weeks as standard chemotherapy. (fujita-hu.ac.jp)
  • On the first day of chemotherapy, 10 mg/m2 of mitomycin C was also given as a single bolus infusion. (fujita-hu.ac.jp)
  • Chemotherapy agents used include 5-FU, mitomycin, and cisplatin. (cancercenterofsouthflorida.com)
  • Two eyes with higher myopia were treated with intraoperative mitomycin-C. (ophthalmologytimes.com)
  • Four weeks after presentation he underwent an excisional biopsy with cryotherapy, intraoperative mitomycin C, absolute alcohol, and an amniotic membrane graft on the left eye. (eyerounds.org)
  • The use of stents or Mitomycin C is therefore not mandatory. (unibo.it)
  • METHODS: The effect of temperature on drug uptake, DNA damage, apoptosis, cell cycle distribution, and cell growth were assessed using the temperature-dependent IC50 and Thermal Enhancement Ratio (TER) values of the chemotherapeutic drugs cisplatin, oxaliplatin, carboplatin, mitomycin-C (MMC), and 5-fluorouracil (5-FU) on 2D and 3D CRC cell cultures at clinically relevant hyperthermic conditions (38-43 °C/60 min). (vumc.nl)
  • The bacteria expressing the rat NADPH: cytochrome P-450 reductase showed increased sensitivity to mitomycin C when incubated with this compound under aerobic conditions. (dundee.ac.uk)
  • abstract = "Mitomycin C and certain analogues alkylate DNA with their C-1 position and cross-link it by a second alkylation involving C-10. (elsevier.com)
  • Purpose: To determine whether adding bevacizumab, with or without mitomycin, to capecitabine monotherapy improves progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) in an open-label, three-arm randomized trial. (edu.au)
  • or capecitabine, bevacizumab, and mitomycin (CBM). (edu.au)
  • Conclusion: Adding bevacizumab to capecitabine, with or without mitomycin, significantly improves PFS without major additional toxicity or impairment of QOL. (edu.au)
  • Mitomycin dosage in mg kg body weight min iv, adjusting the oral route granisetron mg daily occasionally mg daily. (norfolkspca.com)
  • In order to provide further evidence that the lower reductase activity is a factor in the resistance mechanism, we incorporated NADPHxytochrome P-450 reductase into cytotoxicity assays and showed that it significantly sensitizes cells to mitomycin C. Also, the difference in drug sensitivity between the wild-type and drug-resistant Chinese hamster ovary cells was no longer observed. (dundee.ac.uk)
  • The bioreductive activation of mitomycin C (MMC) has been investigated using 10 human cancer cell lines. (hiroshima-u.ac.jp)
  • UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, today announced that it has initiated the rolling submission with the U.S. Food and Drug Administration (FDA) of the New Drug Application (NDA) for UGN-101 (mitomycin gel) for instillation as a treatment for patients with low-grade upper tract urothelial cancer (LG UTUC). (pharmiweb.com)
  • UGN-101 (mitomycin gel) for instillation is an investigational drug formulation of mitomycin in Phase 3 development for the treatment of low-grade upper tract urothelial cancer (LG UTUC). (pharmiweb.com)
  • Uk en publicationsandstatistics chapter benign and malignant tumours in pregnancy gdm is diagnosed near term, blood transfusion are risk factors for haemodynamic instability may be commenced dose of highly publicized claims that ect causes more enduring decits in interpersonal functioning. (norfolkspca.com)
  • Mitomycin sees the largest annual growth in spending per dose over the past 5 years, Robert A. Dowling, MD, reports. (urologytimes.com)
  • The 2,7-diaminomitosenes inhibited L-1210 leukemia cell colony formation in vitro at concentrations 3-4-fold greater (less potent) than mitomycin C. DNA single-strand breaks were also produced by each mitosene, but these lesions did not correlate with cytotoxicity and were less prominent than breaks produced by another monofunctional alkylating agent, methyl methanesulfonate. (elsevier.com)
  • These data provide direct evidence for the role of NADPHxytochrome P-450 reductase in the cytotoxic action of this mitomycin C under aerobic but not hypoxic conditions and suggest that reduced levels of this enzyme can lead to drug resistance. (dundee.ac.uk)
  • Beta irradiation, mitomycin-C and free conjunctival autograft have all been used to reduce the recurrence rate. (columbiaeye.org)
  • The patient underwent topography guided photorefractive keratectomy (PRK) with mitomycin C 30 seconds in the RE. (ocular-surface.org)